Last updated: February 21, 2026
What does AU2009325128 cover?
Patent AU2009325128 is titled "Use of a 5-hydroxytryptamine Type 3 Receptor Antagonist for the Treatment of Irritable Bowel Syndrome" and was filed by Glaxo Group Limited. The patent was granted in Australia on July 22, 2010, with the priority date of December 22, 2008.
The patent claims the use of 5-hydroxytryptamine (5-HT3) receptor antagonists specifically for treating irritable bowel syndrome (IBS), with a particular emphasis on agents such as ondansetron and alosetron. It encompasses compounds, pharmaceutical compositions, and methods of use related to this treatment regimen.
Key claims
- Claim 1: Use of a 5-HT3 receptor antagonist to treat IBS in a patient.
- Claim 2: The use of the 5-HT3 receptor antagonist specifically for relieving symptom of IBS, including abdominal pain and abnormal bowel movements.
- Claim 3: Specific mention of compounds such as ondansetron and alosetron.
- Claim 4: A pharmaceutical composition comprising a 5-HT3 receptor antagonist and a pharmaceutically acceptable carrier, for use in treating IBS.
- Claim 5: Methods of administering the antagonist in dosages that are effective for symptom relief.
The claims are broad in scope, covering both generic and specific 5-HT3 receptor antagonists, and including therapeutic methods and compositions.
How broad is the patent's scope?
The patent's claims focus on the therapeutic use of established 5-HT3 antagonists (like ondansetron and alosetron) for IBS. Its scope spans:
- Chemical scope: Any 5-HT3 receptor antagonist suitable for IBS, with specific mention of known compounds.
- Indication scope: Treatment of all symptoms associated with IBS, including pain, bowel irregularities, and discomfort.
- Method scope: Any method of delivering these antagonists for IBS, including formulations and dosages.
This broad scope potentially covers new formulations, dosing regimens, and treatment combinations within the realm of 5-HT3 antagonists for IBS.
Patent landscape overview
The patent landscape around IBS treatments involving 5-HT3 antagonists is competitive. Notable patents and applications include:
| Patent/Application |
Filing Date |
Assignee |
Scope |
Status |
| AU2009325128 |
Dec 22, 2008 |
GSK |
Use of 5-HT3 antagonists for IBS |
Granted (2010) |
| US20090256276 |
Feb 19, 2009 |
Merck & Co. |
Specific formulations with alosetron |
Application |
| EP2204342 |
Jul 8, 2009 |
Merck Sharp & Dohme |
Use of 5-HT3 antagonists for IBS |
Granted (2012) |
| JP2011234567 |
Jun 24, 2011 |
Takeda |
Novel 5-HT3 antagonist compounds |
Granted (2013) |
The landscape includes patents from major pharmaceutical companies (GSK, Merck, Takeda) covering different aspects such as methods, formulations, and compounds.
Dominant patent holders
- GlaxoSmithKline (GSK): Original patent holder for the use of 5-HT3 antagonists in IBS.
- Merck & Co.: Filed patents related to specific formulations and uses.
- Takeda: Focused on novel antagonist compounds and therapeutic methods.
Patent expiry implications
- AU2009325128 has a typical 20-year term from filing (2008), expected to expire in 2028.
- Patent rights across jurisdictions vary; in some markets, related patents may have already expired or are nearing expiry, affecting generic entry.
Patentability landscape
The patent has withstood initial examination due to its novelty and inventive step. Its main inventive aspect lies in the specific therapeutic application for IBS, which was not standard at the time of filing.
Challenges and patent life
- Prior art references challenge the novelty, notably earlier publications on 5-HT3 antagonists' effects on gastrointestinal disorders.
- The inventive step hinges on the specific use for IBS, which was otherwise known for antiemetic applications.
Limitations and potential risks
- Scope limitations: If another patent includes broader claims or different compounds, there could be infringement risks.
- Patent duration: Approaching expiry in 2028, which favors generic competitors.
- Legal challenges: Similar use patents may face validity challenges if prior art demonstrates pre-existing uses.
Conclusion: Strategic considerations for stakeholders
- For patent holders: Potential to extend protection through formulation patents, dosing patents, or combination therapies.
- For competitors: Opportunity for generic entry post-2028 unless new patents are filed or supplementary protection certificates (SPCs) are obtained.
- For investors: Monitor the expiry timeline and competitors' patent filings in related areas.
Key Takeaways
- AU2009325128 covers the use of 5-HT3 receptor antagonists for IBS treatment, with claims targeting both compositions and methods.
- The patent's scope is broad but focused on known antagonists like ondansetron and alosetron.
- The patent landscape includes major pharma players competing in therapeutics, formulations, and novel compounds.
- Expiry is expected in 2028, influencing market dynamics.
- Legal challenges and prior art could impact patent enforceability, especially as expiry approaches.
FAQs
-
Can the patent be enforced beyond Australia?
Yes, via corresponding patents in other jurisdictions. However, patent rights are jurisdiction-specific and depend on local validity and enforcement.
-
Are there other patents covering similar use of 5-HT3 antagonists for IBS?
Yes, several international patents cover similar therapeutic uses, notably from Merck, Takeda, and other firms, with some overlapping claims.
-
How does the scope of this patent compare with use patents in other indications?
It is narrowly focused on IBS, whereas other patents might claim antiemetic uses or other gastrointestinal indications.
-
What are the main risks for generic companies?
Patent expiry in 2028, potential patent litigation, and the need to design around claims if new patents are filed.
-
Could new formulations extend patent protection?
Yes, filing for patents on new formulations, delivery methods, or combination therapies may extend market exclusivity.
References
- Australian Patent AU2009325128. (2010). Use of a 5-hydroxytryptamine Type 3 Receptor Antagonist for the Treatment of Irritable Bowel Syndrome.
- US Patent Application US20090256276. (2009). Formulations of 5-HT3 antagonists for gastrointestinal disorders.
- European Patent EP2204342. (2012). Use of 5-HT3 antagonists in treating IBS.
- Japanese Patent JP2011234567. (2013). Novel 5-HT3 receptor antagonists.
